Original PaperVariation in survival of patients with lung cancer in Europe, 1985–1989
Introduction
Lung cancer is the most frequent or second most frequent type of cancer among European men and ranks third or higher among European women[1]. Prognosis for both men and women is poor, but it has been reported to have improved for patients with small cell carcinoma since the introduction of chemotherapy in the 1970s2, 3, 4, 5, 6. Besides being dependent on age and tumour stage, survival rates for lung cancer differ according to histological subtype, being better for non-small cell carcinoma than for small cell carcinoma7, 8, 9, 10. In the first EUROCARE study[11], relative 5-year survival rates of lung cancer varied from 6 to 14%, being lowest in England and highest in Switzerland. The collaboration across Europe in the EUROCARE study has now been extended to 45 registries in 17 countries that have accumulated data currently on 3.5 million new patients, most diagnosed between 1978 and 1992. We report on variation in the relative survival of adult patients according to age and histology from 1985–1989 and also explore major time trends since 1978 for most countries.
Section snippets
Patients and methods
Survival analysis was carried out on 173 448 lung cancer cases diagnosed between 1985 and 1989 in 17 countries, recorded in 44 population-based cancer registries. Some registries (Finland, Denmark, Estonia, Slovenia, Iceland, Scotland and Slovakia) cover the whole country, others a large proportion (England) and the rest up to 20% (Italy, Spain, France, The Netherlands, Germany and Sweden). Cases discovered at autopsy, first diagnosed with another tumour, or known only on the basis of a death
Results
Overall relative 1-, 3- and 5-year weighted survival rates for European men were 31, 12 and 10%, respectively and for women 29, 13 and 11%, respectively. Age-standardised survival rates varied greatly within Europe. Relative 1-year survival rates were approximately 40% in Finland, France, The Netherlands and Switzerland and approximately 24% in Denmark, England, Poland and Scotland. Age-standardised relative 5-year survival rates were highest in France, Iceland, The Netherlands, Slovakia and
Discussion
Survival for patients with lung cancer varied considerably within Europe, as illustrated by 1-year relative survival rates, which were lowest for patients in Denmark, Poland and the U.K. and highest for those in Finland, France, The Netherlands and Switzerland. Half of all patients under the age of 45 years died within 1 year of diagnosis, increasing to almost 80% for those aged 75 years or older. Whilst the prognosis for patients with non-small cell carcinoma remained relatively constant
Acknowledgements
The EUROCARE study was financed through the BIOMED programme of the European Union.
References (23)
Analysis of long-term survivors with small-cell lung cancer
Chest
(1993)- et al.
Improvement and plateau in survival of small-cell lung cancer since 1975: a population-based study
Ann Oncol
(1998) - et al.
Introduction: the EUROCARE II study
Eur J Cancer
(1998) - et al.
A computer package for relative survival analysis
Computer Programmes in Biomedicine
(1985) - Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J, eds. Cancer Incidence in Five Continents, Vol VII. IARC Scientific...
- Choi NC, Carey RW, Kaufman D, et al. Small-cell carcinoma of the lung: a progress report of 15 years’ experience....
- Lassen U, Osterlind K, Hansen M, et al. Long-term survival in small-cell lung cancer: posttreatment characteristics in...
- et al.
Longevity in small-cell lung cancer: a report to the Lung Cancer Subcommittee of the United Kingdom Coordinating Committee for Cancer Research
Br J Cancer
(1990) - Sant M, Gatta G, Capocaccia R, et al. Survival for lung cancer in northern Italy. Cancer Causes and Control 1992, 3,...
- Humphrey EW, Smart CR, Winchester DP, et al. National survey of the pattern of care for carcinoma of the lung. J Thorac...
Cited by (118)
Effects of para-toluenesulfonamide intratumoral injection on non-small cell lung carcinoma with severe central airway obstruction: A multi-center, non-randomized, single-arm, open-label trial
2016, Lung CancerCitation Excerpt :Lung cancer is the leading cause of morbidity and mortality among malignant tumors [1] with annually increasing prevalence in China [2]. Despite chemotherapy, radiotherapy and surgery, the 5-year survival rate is 5.0–10.0% [3,4]. In America, one-third of lung cancer patients developed symptomatic malignant airway obstruction [5].
Long-term excess mortality for survivors of non-small cell lung cancer in the Netherlands
2012, Journal of Thoracic OncologyCitation Excerpt :Although the patients included in the SEER are comparable to the general US population regarding income, education, and other parameters, it remains uncertain whether this sample is strictly comparable with the whole population like in the Dutch registries. Within Europe, lung cancer survival rates for Dutch patients were among the highest.39 As populations differ between countries, conditional survival analyses should be conducted on a regular basis in the existing cancer registries worldwide with a view of predicting the prognosis in long-term NSCLC survivors in an appropriate (context-specific) way.
Variation in surgical resection for lung cancer in relation to survival: Population-based study in England 2004-2006
2012, European Journal of CancerCitation Excerpt :In patients with early stage NSCLC, pulmonary resection provides the best form of potentially curative treatment.4 The resection rate in England is reportedly around 10%,5 whereas elsewhere in Europe and the US resection rates of around 20% to 30% are reported.6–8 However, most internationally reported resection rates are quoted as a proportion of those patients with a confirmed tissue diagnosis of NSCLC whereas previous UK data has used the total lung cancer population (including those diagnosed on clinic-radiological grounds only) as the denominator.
- 1
The EUROCARE Working Group for this study is listed in the Appendix A.